[Clinical Study of Blinatumomab in the Treatment of Adult Relapsed/Refractory Ph-Negative Acute B-Lymphoblastic Leukemia].

Min Ouyang,Ya-Yun Zhang,Lin Shi,Jian-Xin Liu,Chun-Jian Wang,Fang Wang,Yao Zhang,Yan Li,Mei-Xiang Zhang,Wen-Qing Hu,Han-Yun Ren,Bin Jiang
DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.05.016
2023-01-01
Abstract:OBJECTIVE:To investigate the efficacy and safety of CD19/CD3 bisecific monoclonalantibody (Blinatumomab) in the treatment of adult patients with relapsed / refractory Ph-negative acute B-lymphoblastic leukemia (R/R-B-ALL).METHODS:Ten adult R/R B-ALL patients were all treated with Blinatumomab. Each treatment cycle was administered for 28 days and stopped for 14 days. The dose was 9 μg/day for the first 7 days of cycle 1, and 28 μg/day for days 8-28 if there were no adverse reactions. From the second cycle onwards, the daily dose was 28 μg. The remission, survival time (EFS and OS) and adverse reactions were observed after treatment.RESULTS:Nine patients with curative effect could be evaluated. Four patients achieved CR after one course, and one patient achieved CR after two courses, the overall remission rate was 55.6%(5/9). The median EFS was 4 months (1-12 months), and the median OS was 6 months (2-44 months). Nine of the 10 patients had fever of different degrees. Serum levels of cytokines such as IL-6, IL-10, IL-17 and IFN-γ increased. Two patients resumed medication after 1 week of treatment interruption due to neurotoxicity and CRS, respectively. One patient was discontinued due to grade 3 CRS and died of tropical candidiaemia.CONCLUSION:Blinatumomab has a good response rate in the treatment of relapsed/refractory B-ALL patients, but the duration of remission is shorter. Drug-related adverse reactions are mainly CRS and neurotoxicity. Inflammatory factors IL-6, IL-10, IL-17 and IFN-γ can be used as indicators to monitor CRS. The bisspecificity MAbs provide an opportunity for subsequent allogeneic hematopoietic stem cell transplantation in R/R-B-ALL patients.
What problem does this paper attempt to address?